The NANOS Annual Meeting Neuro-Ophthalmology Collection: Presentations from the annual meeting of the North American Neuro-Ophthalmology Society (NANOS), a professional organization of more than 600 members who are fully trained ophthalmologists or neurologists. Contains records from the first meeting in 1975 to the present.
NOVEL: https://novel.utah.edu/
TO
| Title | Creator | Relation Is Part Of | ||
|---|---|---|---|---|
| 226 |
 |
Assessing the Impact of Long-Term Idebenone Treatment in Subacute/Dynamic Leber's Hereditary Optic Neuropathy: Results from the LEROS Study | Lorena Castillo Campillo; Nancy Newman; Livia Tomasso; Patrick Yu-Wai-Man; Valerio Carelli; Thomas Klopstock | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 227 |
 |
Assessing the Impact of Long-Term Idebenone Treatment in Chronic Leber's Hereditary Optic Neuropathy: Results from the LEROS Study | Livia Tomasso; Lorena Castillo Campillo; Nancy Newman; Patrick Yu-Wai-Man; Valerio Carelli; Thomas Klopstock | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 228 |
 |
Psychometric Validity of the National Eye Institute Visual Function Questionnaire in Leber Hereditary Optic Neuropathy | Benson Chen; John Britton; Patrick Yu-Wai-Man; Mike Horton | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 229 |
 |
What Can We Learn From the Rate of RNFL Thinning? | Salma Dawoud; Jui-Kai Wang; Joseph Branco; Mark Kupersmith; Randy Kardon | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 230 |
 |
Inappropriate Use of the Term "Papilledema" in the Medical Literature | Brendan Tao; Amir Vosoughi; Edward Margolin; Jonathan Micieli | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 231 |
 |
Association Between Head-Mounted Visual Field Results and Parkinson's Disease Duration and Severity | Annika Patel; Ihtsham Haq; Hounsh Munshi; Eleonore Savatovsky; Ta Chang; Alana Grajewski | NANOS Annual Meeting 2023: Poster Session II: Cognition, Mood & Neuro-degenerative Disease |
| 232 |
 |
Comparison of OCT Disc Area in NAION & Fellow Eyes | Shonar Singh; Andrew Carey; Amanda Henderson | NANOS Annual Meeting 2023: Poster Session II: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) |
| 233 |
 |
Longitudinal Optical Coherence Tomography Indices in Idiopathic Intracranial Hypertension | Rachel Shemesh; Omry Frige; Sharon Garmider; Ruth Huna-Baron | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 234 |
 |
Select Patients with High-Risk Idiopathic Intracranial Hypertension May Be Managed with Medical Therapy Alone | Jeffrey Gluckstein; Amalie Chen; Joseph Rizzo | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 235 |
 |
Pseudotumor Cerebri Patients Can Be Managed Remotely by an OCT-Based Telemedicine Model | Shai Cohen; Tamir Weiss; Meital Ben-Dov; Wahbi Wahbi; Ainat Klein | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 236 |
 |
Weight Loss Resource Utilization in a Cohort of Patients with Idiopathic Intracranial Hypertension | Sarah Pan; Divya Ganugapati; Varalakshmi Niranjan; Lakshmi Leishangthem | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 237 |
 |
The Impact of The COVID-19 Pandemic on Patients with Established Idiopathic Intracranial Hypertension | Michaela Graven-Nielsen; Heather Moss | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 238 |
 |
Effect of Dietician Consultation During Eye Clinic Appointments on Weight Loss in Idiopathic Intracranial Hypertension | Alexander Kwok; Abdelrahman Elhusseiny; Paul Phillips | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 239 |
 |
Weight Loss Barriers and Motivation Assessment Among Patients with Idiopathic Intracranial Hypertension | Lizbeth Gonzalez; Olivia Killeen; Sangeeta Khanna; Wayne Cornblath; Sui Wong; Lindsey De Lott | NANOS Annual Meeting 2023: Poster Session II: Idiopathic Intracranial Hypertension (IIH) |
| 240 |
 |
Predictors of Mortality and Visual Morbidity in Cavernous Sinus Thrombosis | Omar Halawa; Alison Gibbons; Alexandra Van Brummen; Emily Li | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 241 |
 |
Dysmotility in Thyroid Eye Disease: Volumetric and Density Analysis | Joyce Wen; Joy Li; Kristen Park; Shirley Li; Johnny Lee; Kimberly Gokoffski; Alexander Lerner; Vishal Patel; Sandy Zhang-Nunes; Jessica Chang | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 242 |
 |
A First-in-Human Phase 1 Randomized, Singleascending Dose Study of VB421 (lonigutamab), an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers | Gregory Keenan; Timothy Mack; Naveen Daryani; Stephen Thomas | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 243 |
 |
Cobalt Toxicity Induces Optic Neuritis in Mice | Basel Obied; Stephen Richard; Alon Zahavi; Jawad Masalha; Olga Girshevitz; Dror Fixler; Nitza Goldenberg- Cohen | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 244 |
 |
Quantification of Saccadic Fatigability for a Diagnosis of Myasthenia Gravis | Ju-Hee Chae; Sun-Young Oh | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 245 |
 |
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab | Yang Zhao; Jordan Tsai; Rachel Newell; Vahe Bedian | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 246 |
 |
Neurologic Manifestations Associated with Endogenous Endophthalmitis | Dalbert Chen; Sam Karimaghaei; Rupak Dhoot; Alex Wright; Alice Chuang; Ore-ofe Adesina | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 247 |
 |
Detecting Neurodegeneration on Optic Nerve and Cornea in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder | Muhammed Ali Tomris; Cağla Eröz; Mehmet Fatih Yetkin | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 248 |
 |
THRIVE: A Phase 3 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED) | Barrett Katz; Rochelle Summerfelt; Denis O'Shaughnessy | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| 249 |
 |
Characterizing Neurology and Ophthalmology Consults at a Large Tertiary Care Hospital | Mohamad Hassoun; Neena Cherayil; Shira Simon; Nicholas Volpe | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Practice |
| 250 |
 |
The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease | Shwetha Mudalegundi; Peng Huang; Amanda Henderson; Andrew Carey | NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Practice |